Analytical requirements for biochemical bone marker assays

Area of Science:

• Biochemistry
• Clinical Chemistry
• Bone Metabolism Research

Background:

• Established bone turnover markers lack routine laboratory applicability due to comparability and assay influence issues.
• New markers for bone modeling imbalance exist but require validation for routine clinical use.

Purpose of the Study:

• To develop and validate new assays for osteocalcin and C-telopeptides of type I collagen (CrossLaps) suitable for routine laboratory diagnostics.
• To improve the clinical utility of bone turnover markers through enhanced accuracy, interlaboratory comparability, and assay stability.

Main Methods:

• Development of a new osteocalcin assay using monoclonal antibodies to measure intact and N-Mid fragments.
• Utilized a new Elecsys technology for measuring CrossLaps in serum samples.
• Evaluated assay precision, stability, and accuracy for bone disease patient monitoring, including bisphosphonate treatment effects.

Main Results:

• The new osteocalcin assay provides a stable measuring signal, enabling precise bone turnover measurement.
• The serum CrossLaps assay demonstrates high precision (<5%) and improved test component stability.
• The developed assays allow accurate follow-up measurements of treatment effects, such as bisphosphonate therapy.

Conclusions:

• New osteocalcin and serum CrossLaps assays enhance laboratory quality, reliability, and efficiency for routine bone turnover assessment.
• These improved assays facilitate the clinical acceptance of bone turnover markers in routine laboratory settings.
• The advancements support precise monitoring of bone disease and treatment responses.